Compare SYSCO Corporation (SYY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs BIO-TECHNE Corp — how do they compare? SYSCO Corporation trades at $81.58 (market cap $38.25B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: SYSCO Corporation is far larger — about 3.4× BIO-TECHNE Corp's market cap, and SYSCO Corporation pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| SYY | TECH | |
|---|---|---|
Market Cap | $38.25B | $11.34B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $72.48 |
52-Week Low | $69.30 | $43.31 |
Enterprise Value | $51.43B | $11.36B |
Dividend Yield | 2.76% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco Corporation (SYY) trades at $79.84, down 0.26% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported solid Q2 2026 earnings beat ($1.53 vs $1.51 expected) and maintains strong revenue growth, reaching $81.37B in 2025. Recent news highlights the company's $500M AI efficiency program and reaffirmed fiscal 2027 guidance, while analysts maintain a 60% buy rating with $88.25 consensus target.
Sysco presents a compelling investment case with attractive valuation (P/S 0.45), strong institutional interest, and AI-driven efficiency initiatives. However, risks include integration challenges from the Jetro Restaurant Depot acquisition, rising debt levels, and margin pressure from inflationary costs. The stock offers 10% upside to analyst targets but requires monitoring of execution on growth initiatives.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
